GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » LT-Debt-to-Total-Asset

XGN (Exagen) LT-Debt-to-Total-Asset : 0.50 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Exagen LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Exagen's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.50.

Exagen's long-term debt to total assets ratio increased from Sep. 2023 (0.38) to Sep. 2024 (0.50). It may suggest that Exagen is progressively becoming more dependent on debt to grow their business.

Exagen LT-Debt-to-Total-Asset Historical Data

The historical data trend for Exagen's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen LT-Debt-to-Total-Asset Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.34 0.22 0.39 0.39

Exagen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.39 0.43 0.45 0.50

Exagen LT-Debt-to-Total-Asset Calculation

Exagen's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=21.991/56.944
=0.39

Exagen's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=21.775/43.605
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen  (NAS:XGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Exagen LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Exagen's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Exagen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
LMDX AKUMQ CNTG STIM CHEK MYNZ OCX TTOO TRIB DRIO TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
E08A:Germany
Address
1261 Liberty Way, Vista, CA, USA, 92081
Website
https://www.exagen.com
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Chet Burrell director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g.-gpii, Inc. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081